Natco Pharma Updates on Proposed Acquisition of Adcock Ingram Shares
Natco Pharma's Scheme Resolution for acquiring Adcock Ingram shares passed on Oct 9, 2025. Delisting details to follow.
The passing of the Scheme Resolution is a significant step in the acquisition process, which could have a moderate impact on the company's growth and expansion strategies.
The announcement conveys a positive update regarding the acquisition of shares in Adcock Ingram Holdings Limited, as the Scheme Resolution has been passed.
* Natco Pharma provided an update on the proposed acquisition of shares in Adcock Ingram Holdings Limited. * The General Meeting was held on 9 October 2025, where the Scheme Resolution was passed with 98.66% votes in favor. * The Scheme remains subject to the fulfillment or waiver of outstanding conditions. * The final salient dates for the implementation of the Scheme and delisting of Adcock Ingram from the JSE will be announced in due course.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.